Introduction: This sub-analysis evaluated
INTRODUCTION
Increased life expectancy and high global prevalence of type 2 diabetes mellitus [1, 2] render treatment of this condition a lifelong personal and social burden [3] [4] [5] . Post-prandial hyperglycemia is a common phenomenon in people with type 1 and 2 diabetes, and incurs a significant risk of diabetes-related complications [6] . Therefore, achieving control of post-prandial glucose (PPG) level and fasting plasma glucose (FPG) level is important to maintain glycated hemoglobin (HbA 1c ) levels below target [6] . Despite the need to control PPG, the number of available drugs able to accomplish this is limited. Conventional oral glucose-lowering drugs (OGLDs) and lifestyle modifications, while fundamental to early management of the disease, are unable to maintain good glycemic control in the longer term, and there is a consequent additional requirement for exogenous insulin [7, 8] .
Compared with exogenous human insulin, the rapid-acting analog insulin aspart (NovoRapid Ò ; Novo Nordisk A/S, Bagsvaerd, Denmark) is associated with rapid absorption and early onset of action, which facilitates administration immediately before or shortly after a meal [9] . Subcutaneous administration of rapid-acting insulin analogs results in a physiologic profile that bears a closer resemblance to endogenous insulin than is achieved with subcutaneous administration of human insulin. By virtue of this action, insulin analogs, such as insulin aspart, offer advantages over human insulin (e.g., greater convenience [10] ) and have the potential to reduce PPG excursions, thereby improving overall glycemic control [11, 12] . Clinical research shows that insulin aspart is also associated with reduced hypoglycemia risk and greater treatment satisfaction versus human insulin when administered in a basal-bolus regimen among people with type 1 and 2 diabetes mellitus [13] [14] [15] [16] [17] [18] . Guidelines generally recommend initiating insulin therapy when OGLDs fail to provide adequate glycemic control [19] ; in this context, some healthcare professionals start patients on prandial insulin as the only insulin therapy [20, 21] . While few studies have examined the safety and effectiveness of bolus-only insulin aspart, particularly as add-on to OGLDs, available evidence suggests beneficial effects on glycemic control when OGLD therapy is insufficient [22] .
While well-designed randomized controlled trials provide a stringent way of assessing insulin regimens, they focus on a selected patient group under intensive clinical supervision. [20] . In every country, participants gave informed consent and were free to withdraw from the study at any time.
MATERIALS AND METHODS
The study was conducted in accordance with the Declaration of Helsinki of 1964, as revised in 2008 [23] , and Guidelines for Good Pharmacoepidemiology Practice [24] .
Results presented here are from a subanalysis of patients treated with insulin aspart alone or in combination with OGLDs (excluding those who received basal-bolus insulin regimens).
Assessments
Assessments were at baseline (time when the treating physician prescribed insulin aspart), approximately 12 weeks after baseline (results not reported here), and study end (approximately 24 weeks after baseline). weight, and health-related quality of life (HRQoL). HRQoL was measured at baseline and after 24 weeks by self-report using the EQ-5D questionnaire [25] , which evaluates five domains of patient health/lifestyle (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). The questionnaire also includes a rating for an individual's current HRQoL on a visual analog scale [VAS; ranging from 0 (worst imaginable health) to 100 (best imaginable health)]. Scores in the five domains were converted to a single utility value (UK VAS set), with '1.00' indicating 'full health' and '0.00' indicating 'deceased' [26, 27] .
Due to the non-interventional design of the analysis and lack of protocol enforcement to report all outcomes, data are described here as per available reports.
Statistical Analyses
Analyses were performed on data from all patients with a baseline visit who were treated with insulin aspart at least once during the study. For those patients who withdrew from the study, data collected until the date of withdrawal were used for analysis. Patients were split into two cohorts according to whether they had received insulin before the study (insulin-experienced and insulin-naive) or not. Sub-group analyses were then conducted in each cohort according to the number of OGLDs received at baseline (none, one, or Ctwo).
Changes from baseline in effectiveness measures were assessed using Student's paired t test. For hypoglycemia, the percentage of patients reporting at least one event was analyzed using McNemar's test. All statistical analyses were two-sided, using a pre-specified 5% significance level, and were performed by Novo Nordisk A/S using SAS Ò Version 9.1.3
(SAS Ò Institute Inc., Cary, NC, USA).
RESULTS

Study Participants
In total, 3,898 patients from the A 1 chieve study received treatment with insulin aspart alone or in combination with OGLDs at baseline (insulin aspart alone, n = 1,560; insulin aspart ? one OGLD, n = 1,514; and insulin aspart ? Ctwo
OGLDs, n = 824) [20] . Of these, 1,872 patients subsequently switched to insulin analog basalbolus regimens, basal insulin analog regimens, or biphasic insulin analog regimens before completing the study. Thus, 2026 people who received insulin aspart alone or in combination with OGLDs at baseline and after 24 weeks (or last follow-up visit) were included in this analysis (Table 1) .
Among treating physicians, the need to improve glycemic control (93.0%) represented the predominant reason for changing/switching to insulin aspart therapy followed by the need to reduce the risk of hypoglycemia (44.9%) and reduce variability of plasma glucose levels (27.8%). Among insulin-experienced patients (n = 561), previous insulin therapies included premix human insulin (42.1% of patients), human soluble insulin (20.7%), insulin glargine (15.9%), neutral protamine Hagedorn (NPH, 7.0%), NPH plus human soluble insulin (3.6%), and others such as premixed insulin lispro (10.9%). Baseline characteristics were generally similar between patient sub-groups, although insulin-experienced patients appeared to have had longer mean diabetes duration and longer time since OGLD initiation than insulinnaive patients (Table 1 ). In both insulinexperienced and insulin-naive patients, metformin was the most frequently prescribed OGLD pre-study (71% and 80% of patients, respectively), and sulfonylurea was the second most frequently prescribed (44% and 64% of patients, respectively).
Insulin Dose
Insulin-experienced patients received a mean (standard deviation; SD) insulin dose of 0.50 n/a n/a n/a n/a Due to the observational nature of the study not all measures were reported/collected BMI body mass index, OGLDs oral glucose-lowering drugs a In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 548, n = 267, n = 184 and n = 97, respectively; insulin-naive, n = 1,418, n = 506, n = 540 and n = 372, respectively b In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 526, n = 258, n = 182 and n = 86, respectively; insulin-naive, n = 1,388, n = 477, n = 538 and n = 373, respectively c In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 489, n = 246, n = 167 and n = 76, respectively; insulin-naive, n = 1,312, n = 452, n = 506 and n = 354, respectively d In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 556, n = 267, n = 185 and n = 104, respectively; insulin-naive, n = 1,447, n = 505, n = 561 and n = 381, respectively e In the total, no OGLD, one OGLD and Ctwo OGLD groups n = 500, n = 242, n = 160 and n = 98, respectively f In the total, no OGLD, one OGLD and Ctwo OGLD groups: insulin-experienced, n = 530, n = 254, n = 174 and n = 102, respectively; insulin-naive, n = 1,341, n = 467, n = 520 and n = 354, respectively
Diabetes Ther (2013) 4:153-166 157 (0.29) U (or IU)/kg before entering the study.
When patients switched to insulin aspart ± OGLDs at baseline the dose ranged from 0.45 to 0.47 U/kg in the different subgroups ( Fig. 1) . In the insulin-naive cohort, mean (SD) insulin aspart dose was 0.40 (0.20) U/kg at baseline (Fig. 1) . Following 24 weeks' therapy with insulin aspart, there were no obvious changes from baseline in mean insulin dose in either cohort (Fig. 1) . 
Number of OGLDs
Most insulin-experienced and insulin-naive patients were receiving the same number of
OGLDs at baseline and following 24 weeks of treatment with insulin aspart (Table 2 ). Most Insulin-experienced Insulin-naive Fig. 1 Mean (SD) insulin dose received by patients at baseline and after 24 weeks on insulin aspart therapy in the A 1 chieve study. Due to the observational nature of the study not all measures were reported/collected. At baseline: insulin-experienced: n = 257 in 0 OGLD sub-group; n = 182 in 1 OGLD sub-group; n = 86 in C2 OGLDs sub-group. Insulin-naive: n = 477 in 0 OGLD sub-group; n = 536 in 1 OGLD sub-group; n = 373 in C2 OGLDs sub-group. After 24 weeks: insulin-experienced: n = 178 in 0 OGLD sub-group; n = 138 in 1 OGLD sub-group; n = 64 in C2 OGLDs sub-group. Insulin-naive: n = 326 in 0 OGLD sub-group; n = 422 in 1 OGLD sub-group; n = 274 in C2 OGLDs sub-group. OGLD oral glucoselowering drug Metformin and/or sulfonylureas were the predominant OGLDs administered in all subgroups of patients; [60% of patients in all subgroups were receiving metformin after 24 weeks.
Serious Adverse Events
Following 24 weeks of insulin aspart therapy, six serious adverse events (SAEs) were reported, which were considered unlikely to be related to the study treatment. In the insulin-naive cohort, three SAEs (one incident of acute cardiac failure, one malignant lung neoplasm, and one case of chronic renal failure) were reported in the group receiving no OGLDs at baseline and one SAE (vascular stenosis) was reported in the group receiving one OGLD at baseline; two deaths (one acute cardiac failure and the other malignant lung neoplasm) were reported in the insulin-naive cohort. In the insulin-experienced cohort, two SAEs were reported in the group receiving no OGLDs at baseline: upper gastrointestinal hemorrhage and hepatic coma. No other SAEs were reported.
Hypoglycemia Events
The proportion of insulin-experienced and insulin-naive patients reporting at least one hypoglycemia event was significantly decreased from baseline following 24 weeks of treatment with insulin aspart in patients receiving bid or tid insulin injections ( Table 3) . The proportion of patients reporting at least one hypoglycemia event did not significantly change between baseline and 24 weeks in patients receiving qd or four times daily (qid) insulin injections Due to the observational nature of the study not all measures were reported/collected OGLDs oral glucose-lowering drugs (Table 3 ). There was no obvious effect of insulin injection frequency on the proportion of patients experiencing nocturnal hypoglycemia events at 24 weeks in insulin-experienced and insulin-naive patients ( Table 3) . The proportion of patients reporting at least one hypoglycemia event was significantly decreased from baseline following 24 weeks of treatment with insulin aspart, irrespective of prior insulin experience and the number of OGLDs received at baseline (Table 4) ; the exception was no significant change between baseline and 24 weeks in insulin-naive patients who were receiving no OGLDs at baseline. The proportion of patients reporting at least one nocturnal hypoglycemia event was significantly decreased from baseline to 24 weeks irrespective of prior insulin experience and the number of OGLDs received at baseline; the exceptions were no change between baseline and 24 weeks in insulin-experienced patients taking Ctwo
OGLDs at baseline, and insulin-naive patients taking no OGLDs at baseline (Table 4) .
At 24 weeks, no major hypoglycemia events were reported in the insulin-experienced or insulin-naive cohorts and the risk of nocturnal hypoglycemia was reduced to \0.6 events/ person-year, irrespective of baseline insulin Table 5 ). There were no obvious differences in these parameters between sub-groups (Table 5) .
Body Weight
Body weight remained stable throughout the study for insulin-experienced patients, irrespective of the number of OGLDs received (Table 5 ). In the insulin-naive cohort, there was a significant mean weight gain (0.6 kg) from baseline at 24 weeks in patients receiving no
OGLDs at baseline and a significant weight loss (-0.2 kg) in the sub-group receiving Ctwo
OGLDs at baseline (Table 5) . Change after 24 weeks -1.7 (1.9)*** -1.6 (2.1)*** -1.9 (1.9)*** -1.7 (1.6)*** -2.2 (2.0)*** -2.1 (2.2)*** -2.4 (2.0)*** -2. (23) 75 (24) 78 (23) 76 (17) 80 (21) 79 (24) 83 (21) 78 (16) 24 weeks 57 (12) 57 (13) 58 (12) 58 (11) 55 (12) measures across all sub-groups in both the insulin-naive and insulin-experienced cohorts; Table 5 ).
DISCUSSION
In [29] . Overall, 52% of the patients who switched to/initiated therapy with insulin aspart alone or in combination with OGLDs continued on this insulin regimen for the duration of the study. In the INSTIGATE study, 31% of the total cohort who were receiving prandial insulin at baseline continued to be managed on this regimen after 2 years of treatment [29] . These data suggest that a prandial insulin regimen is able to effectively control glucose levels over an extended time in many patients. 
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